|
|
|
Volumn 61, Issue 2 Suppl, 1998, Pages 27-29
|
|
Clinical efficacy and safety of tazarotene: optimizing clinical results.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CORTICOSTEROID;
DERMATOLOGICAL AGENT;
NICOTINIC ACID DERIVATIVE;
TAZAROTENE;
CLINICAL TRIAL;
DOSE RESPONSE;
DRUG COMBINATION;
HUMAN;
PILOT STUDY;
PROGNOSIS;
PSORIASIS;
REVIEW;
TOPICAL DRUG ADMINISTRATION;
TREATMENT OUTCOME;
ADMINISTRATION, TOPICAL;
ADRENAL CORTEX HORMONES;
CLINICAL TRIALS;
DERMATOLOGIC AGENTS;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG THERAPY, COMBINATION;
HUMANS;
NICOTINIC ACIDS;
PILOT PROJECTS;
PROGNOSIS;
PSORIASIS;
TREATMENT OUTCOME;
|
|
EID: 0031987861
PISSN: 00114162
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (6)
|
|
References (6)
|
